IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Maternal TDF and FTC to Reduce NNRTI Resistance Mutations After Intrapartum NVP (TD-2)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| HIV Pregnancy | Drug: Combination tenofovir-emtricitabine | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Addition of Single-dose, Maternal Tenofovir and Emtricitabine to Reduce Non-nucleoside Reverse Transcriptase Inhibitor Resistance Mutations in the Setting of Zidovudine and Nevirapine for Prevention of Mother-to-child HIV Transmission |
- maternal antiretroviral drug resistance to non-nucloeoside reverse transcriptase inhibitors [ Time Frame: 6 weeks ]
- maternal antiretroviral drug resistance to non-nucloeoside reverse transcriptase inhibitors [ Time Frame: 2 weeks ]
- maternal hematological and renal function after TDF-FTC use [ Time Frame: 6 weeks ]
| Enrollment: | 400 |
| Study Start Date: | March 2005 |
| Study Completion Date: | May 2007 |
| Primary Completion Date: | May 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: combination tenofovir-emtricitabine |
Drug: Combination tenofovir-emtricitabine
Tenofovir disoproxil 300 mg / emtricitabine 200 mg taken as a single dose during labor
Other Name: Truvada
|
| No Intervention: control arm |
Detailed Description:
Single-dose intrapartum and neonatal nevirapine (NVP), either alone or in combination with short course zidovudine (ZDV) is in widespread use to prevent mother-to-child HIV transmission throughout the developing world. Though the public health benefits cannot be overstated, widespread use of NVP in this fashion may come at a cost. Non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations are induced in at least 20% and probably a larger proportion of women exposed to NVP in this fashion. Addition of short-course ZDV does not appear to mitigate this effect substantially. The full implications of these NVP resistance mutations are yet unknown, though there is concern that they may result in reduced efficacy of the NVP or other NNRTIs in long-term, therapeutic regimens.
We are conducting a clinical trial of tenofovir (TDF) and emtricitabine (FTC), marketed as a fixed dose combination, Truvada ™, to reduce NNRTI-resistance post-delivery in the setting of NVP with or without ZDV for PMTCT. TDF and FTC are both Category B drugs and are approved for use in pregnancy. They have several characteristics that make them ideal candidate drugs for use in conjunction with NVP, including long intracellular half-lives and established safety profile among adults for HIV treatment.
Women will be enrolled between 28 and 38 weeks of gestation. As part of normal PMTCT services, they may choose NVP-boosted ZDV or single dose NVP for PMTCT; We anticipate that most (~80%) will choose the former. At arrival for delivery, they will be randomized to receive either the two study drugs (intervention) or no drug (control). A total of 400 women will be randomized, and followed, along with their infants, for 6 months.
Eligibility| Ages Eligible for Study: | 16 Years and older (Child, Adult, Senior) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Serologically confirmed HIV infection;
- Gestational age of 28 to 38 weeks;
- Previous selection of a NVP-based PMTCT regimen (with or without ZDV)
- Willingness to participate in a randomized trial;
- Willingness to follow up in a postpartum visit schedule;
- Willingness to allow her infant to participate in this trial;
Exclusion Criteria:
- Use of antiretroviral medications before this pregnancy, even in a single dose.
- Current use of antiretroviral medications for treatment of advanced HIV disease and/or AIDS
- Illness or complication of pregnancy likely to warrant transfer to the University Teaching Hospital (UTH), known at time of randomization;
- Known or suspected allergy to NVP or other benzodiazepine medications;
- History of known liver disease.
- Hemoglobin level of 7.9 g/dL or less
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00204308
| Zambia | |
| Kalingalinga Health Centre | |
| Lusaka, Zambia | |
| Kanyama Health Centre | |
| Lusaka, Zambia | |
| Principal Investigator: | Jeffrey S A Stringer, MD | University of Alabama at Birmingham |
| Study Director: | Benjamin H Chi, MD | University of Alabama at Birmingham |
More Information
Publications:
| Responsible Party: | Benjamin Chi, MD, MSc, Associate Professor, University of North Carolina, Chapel Hill |
| ClinicalTrials.gov Identifier: | NCT00204308 History of Changes |
| Other Study ID Numbers: |
EGSA 19-02 |
| Study First Received: | September 12, 2005 |
| Last Updated: | May 30, 2012 |
Keywords provided by Benjamin Chi, MD, MSc, University of North Carolina, Chapel Hill:
|
HIV Pregnancy Mother-to-child transmission of HIV |
Drug resistance Nevirapine resistance NNRTI resistance |
Additional relevant MeSH terms:
|
Nevirapine Tenofovir Emtricitabine Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Anti-HIV Agents Cytochrome P-450 CYP3A Inducers Cytochrome P-450 Enzyme Inducers |
ClinicalTrials.gov processed this record on June 28, 2017